Kura Oncology Inc ASH Virtual Investor Event Transcript
Good morning, good afternoon, everyone. My name is Troy Wilson, and I am the President and CEO of Kura Oncology. It's a pleasure to welcome all of you today to our investor event, where we'll be discussing the data that was just presented at the American Society of Hematology meeting just a few minutes ago.
I want to take a minute before we get started and just introduce the other participants on the line. I'm joined by Dr. Stephen Dale, Kura's Chief Medical Officer; Dr. Bridget Martell, Kura's Senior Scientific Advisor; Dr. Eunice Wang, one of the key investigators on the study from Roswell Park; Dr. Ghayas Issa from MD Anderson; Dr. Francis Burrows, who's our VP of Translational Research. Dr. Blake Tomkinson, our Head of Portfolio Strategy and Program Management. I believe I've covered all of the participants.
Before we get started, obviously, just need to make a forward-looking statement. The presentation and the comments that you hear today are going to be subject to forward-looking statement language. We would
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |